Among the vector-borne diseases, malaria has been the most devastating in terms of human health. Plasmodium which causes malaria have dramatic health and economic effects worldwide. Malaria disease has not been under control due to parasite's complex biology, antigenic diversity and genomic plasticity. Any vaccine or other biological approaches has not been successful against the disease so far. Using restricted amino acid phage display libraries, we have been developing antibody fragments against proteins that are involved in complex life cycle of the parasite.
The other project our lab has been working on is in the field of Chimeric Antigen Receptor (CAR) T-cell therapy, which is known as the new generation of treatment in hematological cancer types such as acute lymphoblastic leukemia (ALL), lymphoma and multiple myeloma.
Current multiple myeloma and acute lymphoblastic chimeric antigen receptors utilize single chain variable fragment (scFv) which is taken from a particular monoclonal antibody in order to be employed in CAR T-cell therapy. We aim to replace ScFv fragments within the CAR with other type of antibody and antibody like scaffolds and create novel CAR-T cells for variety of cancer types.